

## Disitamab

Cat. No.:	HY-P99854
CAS No.:	2185868-98-6
Target:	EGFR; ADC Antibody
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin ( <a href="#">Disitamab vedotin (HY-P9985)</a> ) <sup>[1]</sup> .
IC <sub>50</sub> & Target	HER2
In Vivo	Disitamab (27 mg/kg; i.v.; once; 5 mL/kg) shows no significant toxicity in monkeys <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Jiang J, et al. Preclinical safety profile of disitamab vedotin—a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA